Miletus
Intellectual Property Management LLP
Miletus Intellectual Property Management (MIM) is an IP asset management firm with an independent legal practice at its core. We help companies, research institutions, and investors manage intellectual property deliberately by aligning IP strategy, legal execution, and commercialization across the full lifecycle of innovation—preserving optionality, controlling risk, and positioning portfolios for long-term value creation.
Managing Intellectual Property as an Asset Class
THE PROBLEM
The Traditional Law Firm Model Is Structurally Misaligned
Intellectual property is a long‑lived, option‑rich asset. Yet it is still managed through models optimized for selling legal time or processing filings.
The result:
Valuable IP is abandoned when it falls outside a core strategy
Technology transfer efforts are overbuilt and underperforming
Legal spend is unpredictable and difficult to govern
Commercialization opportunities are missed
OUR APPROACH
IP as an Asset Class
MIM treats intellectual property as a managed asset rather than a series of isolated legal tasks.
Our work emphasizes:
Portfolio construction and rebalancing
Selective investment in commercializable assets
Optionality preservation for non‑core but not non‑valuable IP
Downside protection through cost and risk discipline
Transaction readiness for licensing, spin‑outs, and acquisitions
Independent Legal Practice
Legal Rigor Without Law‑Firm Constraints
MIM operates as an independent legal practice. From a client’s perspective, the attorney–client relationship and privilege protections are identical to those of any traditional law firm.
Licensed attorneys and patent agents under partner oversight
Formal engagement letters and full attorney–client privilege
Patent prosecution, strategy, and transactions delivered within the legal engagement
Where appropriate, clients may separately access non‑legal capabilities through strategic partners—without compromising privilege or independence.
Who We Serve
Startups & Operating Companies
Strategic IP management and monetization across the full lifecycle of innovation for startups and operating companies across diverse technology areas, with particular depth in complex, science-driven technologies.
Biotech & Pharma Companies
Strategic management and monetization of biotech and pharma IP portfolios—especially non-core but valuable assets—focused on cost stability, optionality preservation, and value realization.
Research Institutes & Foundations
Portfolio-first technology transfer support that prioritizes commercializable assets and improves licensing and monetization outcomes.
Private Equity & Venture Capital
Identification, evaluation, and diligence of investible technologies and companies, together with IP strategy and execution support for portfolio companies post-investment.
Litigation Funders
Full-spectrum IP diligence and monetization support, including downside risk analysis, portfolio stewardship, identification of licensing and strategic partners, asset acquisitions, and IP assertion strategies where appropriate.
Why MIM
Designed for Outcomes, Not Hours
Traditional law firms execute legal tasks. MIM manages IP portfolios for outcomes.
Clients work with MIM to:
Convert unpredictable legal spend into a portfolio operating cost
Improve commercialization and monetization results
Access senior IP and commercialization expertise without permanent overhead
Align IP strategy with business, scientific, and financial objectives
Technology as Infrastructure
MIM leverages modern automation and technology as operational infrastructure, enabling:
Predictable execution
Scalable portfolio management
High accuracy and consistency
Cost‑effective operations without traditional firm overhead
We do not sell tools. We deliver results.
Leadership
MIM is led by senior professionals with decades of combined experience at the highest levels of intellectual property law, life sciences, corporate transactions, and company building. The leadership team brings together deep technical training, top-tier legal experience, and real-world operating and capital-markets perspective. Collectively, the founders have advised on large, complex IP portfolios, supported licensing and M&A transactions, built and scaled biotechnology companies, and worked directly with investors, boards, and management teams. This breadth allows MIM to manage IP not only as a legal construct, but as a strategic and financial asset positioned for long-term value creation.
Christopher Jeffers, Ph.D., J.D.
Attorney, life sciences operator, and venture builder with deep experience spanning IP strategy, licensing, company formation, and commercialization. Dr. Jeffers has served in senior legal and executive roles, founded and scaled biotechnology companies, and teaches at leading engineering and business schools at the intersection of technology, IP, and innovation. His legal career includes partner-level and senior roles at top-tier IP and AmLaw-ranked firms.
Co-Founder
Eric Broyles, J.D.
Former senior corporate attorney turned entrepreneur and platform builder with extensive experience in transactions, governance, and capital formation. Mr. Broyles brings an operating and capital-markets perspective to IP portfolio strategy, monetization, and transaction readiness. His legal background includes senior associate and partner-level experience at leading AmLaw-ranked firms, as well as serving as senior in-house counsel at a publicly traded technology and media company, before transitioning to company building and investing.
Senior Advisor
XXXX, Ph.D., J.D.
Patent attorney with more than two decades of experience in life sciences and chemical IP strategy, portfolio management, and transactions. Dr. XXXX has led the drafting and prosecution of large, complex patent portfolios and focuses on aligning IP strategy with commercialization, financing, and long-term asset value. He previously practiced as a partner at leading IP boutiques and AmLaw-ranked firms and has served as an adjunct professor teaching patent law and licensing.
Co-Founder
MIM maintains a strategic alignment with Miletus Biotechnology, a separate life sciences advisory and operating organization. Where appropriate, this relationship allows clients to access non-legal capabilities across scientific development and commercialization through separate engagements—while preserving MIM’s independence as legal counsel and full attorney–client privilege.
Supporting the Full Lifecycle of Biotech Innovation
Let’s Reframe How IP is Managed
Whether you are managing IP portfolios, rethinking technology transfer, or evaluating an investment or transaction, MIM provides a disciplined, outcome‑oriented approach to intellectual property.